Curated News
By: NewsRamp Editorial Staff
April 20, 2026
MindBio Launches AI Tool for Broader Drug & Alcohol Detection
TLDR
- MindBio's Intox Collect technology gives companies a competitive edge by enhancing workplace safety and compliance through advanced intoxication detection across multiple substances.
- MindBio's AI platform analyzes voice and facial recognition data using over 50 million data points to detect various CNS stimulants and depressants beyond just alcohol.
- This technology makes workplaces safer by preventing accidents in high-risk industries like mining and aviation, creating a better tomorrow through enhanced public safety.
- MindBio is developing Edge AI kiosks for enterprise deployment, with prototype testing expected in 2026, expanding intoxication detection to new industries.
Impact - Why it Matters
This development matters because it addresses critical safety gaps in high-risk industries where impairment can lead to catastrophic accidents. Traditional testing methods often detect only alcohol or require invasive procedures, while MindBio's AI-driven approach using voice and facial recognition could provide faster, more comprehensive screening for multiple substances. For workers in mining, aviation, construction, and law enforcement, this technology could mean safer workplaces through more effective impairment detection. For employers, it offers enhanced compliance tools and potentially reduced liability. As substance use patterns evolve, particularly with prescription medications and other CNS-affecting drugs, this broader detection capability becomes increasingly vital for preventing workplace accidents and saving lives.
Summary
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company pioneering AI-driven voice analytics for intoxication detection, has launched Intox Collect™, a groundbreaking software tool that significantly expands its artificial intelligence-based platform. This innovative technology enhances the company's ability to collect and analyze voice and facial recognition data tied to drug and alcohol impairment, moving beyond traditional alcohol detection to include multiple central nervous system stimulants and depressants. With an AI model currently utilizing more than 50 million data points—and management expecting that figure to increase further—MindBio is positioning itself at the forefront of next-generation safety technology for high-risk industries.
The company's expansion into broader substance detection comes with ambitious hardware development plans, including Edge AI kiosk hardware for enterprise deployment with prototype testing expected in the second quarter of 2026. Target industries include mining, aviation, construction, law enforcement, and any environments where intoxication testing is frequently required for safety and compliance. This technological advancement represents a significant leap forward from conventional testing methods, offering potentially faster, more comprehensive impairment detection through non-invasive voice and facial analysis rather than traditional blood or breath tests.
For those interested in learning more about this development, additional details are available through TechMediaWire's coverage of MindBio Therapeutics Corp. The company's newsroom at https://ibn.fm/MBQIF provides the latest updates relating to MBQIF, while TechMediaWire itself operates as a specialized communications platform within the Dynamic Brand Portfolio @ IBN, delivering comprehensive distribution services for technology companies. This launch positions MindBio as a key player in the evolving landscape of workplace safety technology, potentially transforming how industries approach impairment detection and prevention.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, MindBio Launches AI Tool for Broader Drug & Alcohol Detection
